DiaMedica Therapeutics (DMAC) Receivables - Accured (2019 - 2026)
DiaMedica Therapeutics' (DMAC) quarterly Receivables - Accured came in at $285000.0 in Q1 2026, up 24.45% year-on-year from $229000.0 in Q1 2025, and up 14.0% quarter-over-quarter from $250000.0 in Q4 2025.
DiaMedica Therapeutics (DMAC) Receivables - Accured (2019 - 2026) Analysis & Trends
DiaMedica Therapeutics' Receivables - Accured history runs 8 years deep, the most recent figure standing at $285000.0 for Q1 2026.
- On a quarterly basis, Receivables - Accured rose 24.45% year-over-year to $285000.0 in Q1 2026; TTM through Mar 2026 was $285000.0, a 24.45% increase from a year earlier, with the FY2025 full-year figure at $250000.0, up 6.38% from the prior year.
- Receivables - Accured rose to $285000.0 in Q1 2026 per DMAC's latest filing, from $250000.0 in the prior quarter.
- Across five years, Receivables - Accured topped out at $391000.0 in Q1 2024 and bottomed at $55000.0 in Q1 2023.
- The 5-year median for Receivables - Accured is $229000.0 (2025), against an average of $217058.8.
- Across the five-year window, Receivables - Accured soared 877.78% in 2022 and tumbled 66.87% in 2023, its largest moves.
- Year by year, Receivables - Accured stood at $80000.0 in 2022, then surged by 272.5% to $298000.0 in 2023, then slipped by 21.14% to $235000.0 in 2024, then increased by 6.38% to $250000.0 in 2025, then grew by 14.0% to $285000.0 in 2026.
- Per Business Quant, the three latest DMAC Receivables - Accured figures stand at $285000.0 (Q1 2026), $250000.0 (Q4 2025), and $228000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | DiaMedica Therapeutics | 366.87 Mn | 366.87 Mn | - | 285,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 285,000.00 |
| Mar 31, 2026 | 285,000.00 |
| Dec 31, 2025 | 250,000.00 |
| Dec 31, 2025 | 250,000.00 |
| Sep 30, 2025 | 228,000.00 |
| Sep 30, 2025 | 228,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Jun 30, 2025 | 142,000.00 |
| Mar 31, 2025 | 229,000.00 |
| Mar 31, 2025 | 229,000.00 |
| Dec 31, 2024 | 235,000.00 |
| Dec 31, 2024 | 235,000.00 |
| Sep 30, 2024 | 288,000.00 |
| Sep 30, 2024 | 288,000.00 |
| Jun 30, 2024 | 387,000.00 |
| Jun 30, 2024 | 387,000.00 |
| Mar 31, 2024 | 391,000.00 |
| Mar 31, 2024 | 391,000.00 |
| Dec 31, 2023 | 298,000.00 |
| Dec 31, 2023 | 298,000.00 |